These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 37144579)

  • 21. Broadly neutralizing antibodies and long-acting antiretroviral drugs as treatments for HIV.
    Kuritzkes DR
    Curr Opin HIV AIDS; 2023 Jul; 18(4):225-228. PubMed ID: 37265259
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Can Broadly Neutralizing HIV-1 Antibodies Help Achieve an ART-Free Remission?
    Hsu DC; Mellors JW; Vasan S
    Front Immunol; 2021; 12():710044. PubMed ID: 34322136
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design of an optimal combination therapy with broadly neutralizing antibodies to suppress HIV-1.
    LaMont C; Otwinowski J; Vanshylla K; Gruell H; Klein F; Nourmohammad A
    Elife; 2022 Jul; 11():. PubMed ID: 35852143
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sensitivity to Broadly Neutralizing Antibodies of Recently Transmitted HIV-1 Clade CRF02_AG Viruses with a Focus on Evolution over Time.
    Stefic K; Bouvin-Pley M; Essat A; Visdeloup C; Moreau A; Goujard C; Chaix ML; Braibant M; Meyer L; Barin F
    J Virol; 2019 Jan; 93(2):. PubMed ID: 30404804
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Broadly neutralizing antibodies against HIV-1 and concepts for application.
    Gruell H; Schommers P
    Curr Opin Virol; 2022 Jun; 54():101211. PubMed ID: 35306354
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A calculated risk: Evaluating HIV resistance to the broadly neutralising antibodies10-1074 and 3BNC117.
    Zacharopoulou P; Ansari MA; Frater J
    Curr Opin HIV AIDS; 2022 Nov; 17(6):352-358. PubMed ID: 36178770
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antibody interventions in HIV: broadly neutralizing mAbs in children.
    Ajibola G; Masheto G; Shapiro R
    Curr Opin HIV AIDS; 2023 Jul; 18(4):217-224. PubMed ID: 37278286
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Broadly neutralizing antibodies combined with latency-reversing agents or immune modulators as strategy for HIV-1 remission.
    Gunst JD; Højen JF; Søgaard OS
    Curr Opin HIV AIDS; 2020 Sep; 15(5):309-315. PubMed ID: 32675575
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection.
    Wagh K; Bhattacharya T; Williamson C; Robles A; Bayne M; Garrity J; Rist M; Rademeyer C; Yoon H; Lapedes A; Gao H; Greene K; Louder MK; Kong R; Karim SA; Burton DR; Barouch DH; Nussenzweig MC; Mascola JR; Morris L; Montefiori DC; Korber B; Seaman MS
    PLoS Pathog; 2016 Mar; 12(3):e1005520. PubMed ID: 27028935
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vertical HIV-1 Transmission in the Setting of Maternal Broad and Potent Antibody Responses.
    Tu JJ; Kumar A; Giorgi EE; Eudailey J; LaBranche CC; Martinez DR; Fouda GG; Moreau Y; Thomas A; Montefiori D; Gao F; Sagar M; Permar SR
    J Virol; 2022 Jun; 96(11):e0023122. PubMed ID: 35536018
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller.
    Freund NT; Wang H; Scharf L; Nogueira L; Horwitz JA; Bar-On Y; Golijanin J; Sievers SA; Sok D; Cai H; Cesar Lorenzi JC; Halper-Stromberg A; Toth I; Piechocka-Trocha A; Gristick HB; van Gils MJ; Sanders RW; Wang LX; Seaman MS; Burton DR; Gazumyan A; Walker BD; West AP; Bjorkman PJ; Nussenzweig MC
    Sci Transl Med; 2017 Jan; 9(373):. PubMed ID: 28100831
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neutralization Synergy between HIV-1 Attachment Inhibitor Fostemsavir and Anti-CD4 Binding Site Broadly Neutralizing Antibodies against HIV.
    Zhang Y; Chapman JH; Ulcay A; Sutton RE
    J Virol; 2019 Feb; 93(4):. PubMed ID: 30518644
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HIV-1 Coreceptor Usage and Variable Loop Contact Impact V3 Loop Broadly Neutralizing Antibody Susceptibility.
    Registre L; Moreau Y; Ataca ST; Pulukuri S; Henrich TJ; Lin N; Sagar M
    J Virol; 2020 Jan; 94(2):. PubMed ID: 31694950
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Replacement of Antiretroviral Therapy with HIV Broadly Neutralizing Antibodies to Maximize the Effectiveness of Chemotherapy in HIV Patients with Lung Cancer.
    Atkinson B; Abassi A; Sajadi MM; Tehrani ZR; Le NM; Chen HH; Sausville E; DeVico AL; Lewis GK; Fan X; Heredia A
    AIDS Res Hum Retroviruses; 2023 Sep; 39(9):475-481. PubMed ID: 37053110
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vaccinal effect of HIV-1 antibody therapy: dream or reality?
    Naranjo-Gomez M; Pelegrin M
    Curr Opin HIV AIDS; 2023 Jul; 18(4):209-216. PubMed ID: 37144564
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Probabilities of developing HIV-1 bNAb sequence features in uninfected and chronically infected individuals.
    Kreer C; Lupo C; Ercanoglu MS; Gieselmann L; Spisak N; Grossbach J; Schlotz M; Schommers P; Gruell H; Dold L; Beyer A; Nourmohammad A; Mora T; Walczak AM; Klein F
    Nat Commun; 2023 Nov; 14(1):7137. PubMed ID: 37932288
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Of Mice, Macaques, and Men: Broadly Neutralizing Antibody Immunotherapy for HIV-1.
    Nishimura Y; Martin MA
    Cell Host Microbe; 2017 Aug; 22(2):207-216. PubMed ID: 28799906
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Broadly neutralizing antibody responses in the longitudinal primary HIV-1 infection Short Pulse Anti-Retroviral Therapy at Seroconversion cohort.
    Granger LA; Huettner I; Debeljak F; Kaleebu P; Schechter M; Tambussi G; Weber J; Miro JM; Phillips R; Babiker A; Cooper DA; Fisher M; Ramjee G; Fidler S; Frater J; Fox J; Doores KJ
    AIDS; 2021 Nov; 35(13):2073-2084. PubMed ID: 34127581
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Human Ig knockin mice to study the development and regulation of HIV-1 broadly neutralizing antibodies.
    Verkoczy L; Alt FW; Tian M
    Immunol Rev; 2017 Jan; 275(1):89-107. PubMed ID: 28133799
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-V1/V3-glycan broadly HIV-1 neutralizing antibodies in a post-treatment controller.
    Molinos-Albert LM; Baquero E; Bouvin-Pley M; Lorin V; Charre C; Planchais C; Dimitrov JD; Monceaux V; Vos M; ; Hocqueloux L; Berger JL; Seaman MS; Braibant M; Avettand-Fenoël V; Sáez-Cirión A; Mouquet H
    Cell Host Microbe; 2023 Aug; 31(8):1275-1287.e8. PubMed ID: 37433296
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.